Stock analysts at Guggenheim began coverage on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in a research note issued on Monday, The Fly reports. The firm set a “buy” rating on the stock.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald restated an “overweight” rating and set a $62.00 target price (up from $56.00) on shares of Aerie Pharmaceuticals in a research note on Thursday, July 20th. Canaccord Genuity restated a “positive” rating and set a $73.00 target price (up from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, July 24th. Mizuho restated a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $76.00 price target (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Two analysts have rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $68.92.

Aerie Pharmaceuticals (AERI) traded down 2.76% during midday trading on Monday, hitting $63.30. The company had a trading volume of 605,947 shares. The stock’s market capitalization is $2.30 billion. The stock has a 50 day moving average price of $56.74 and a 200-day moving average price of $51.50. Aerie Pharmaceuticals has a 52 week low of $32.05 and a 52 week high of $66.10.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.02. On average, equities analysts predict that Aerie Pharmaceuticals will post ($2.59) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Aerie Pharmaceuticals, Inc. (AERI) Research Coverage Started at Guggenheim” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/23/aerie-pharmaceuticals-inc-aeri-research-coverage-started-at-guggenheim.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Aperio Group LLC boosted its stake in shares of Aerie Pharmaceuticals by 4.7% in the second quarter. Aperio Group LLC now owns 4,914 shares of the company’s stock worth $258,000 after buying an additional 219 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Aerie Pharmaceuticals by 11.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after buying an additional 275 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Aerie Pharmaceuticals by 7.4% in the second quarter. Legal & General Group Plc now owns 7,534 shares of the company’s stock worth $396,000 after buying an additional 519 shares during the last quarter. Bamco Inc. NY boosted its stake in shares of Aerie Pharmaceuticals by 13.4% in the second quarter. Bamco Inc. NY now owns 5,511 shares of the company’s stock worth $290,000 after buying an additional 653 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Aerie Pharmaceuticals by 5.5% in the second quarter. The Manufacturers Life Insurance Company now owns 23,501 shares of the company’s stock worth $1,235,000 after buying an additional 1,235 shares during the last quarter. Hedge funds and other institutional investors own 94.64% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

The Fly

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.